Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: firstname.lastname@example.org. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Current Trends Classification System for Human T-Lymphotropic Virus Type III/ Lymphadenopathy-Associated Virus Infections
Persons infected with the etiologic retrovirus of acquired immunodefi- ciency syndrome (AIDS) (1-4) * may present with a variety of manifestations ranging from asymptomatic infection to severe immunodeficiency and life- threatening secondary infectious diseases or cancers. The rapid growth of knowledge about human T-lymphotropic virus type III/lymphadenopathy- associated virus (HTLV-III/LAV) has resulted in an increasing need for a system of classifying patients within this spectrum of clinical and laboratory findings attributable to HTLV-III/LAV infection (5-7).
Various means are now used to describe and assess patients with manifes- tations of HTLV-III/LAV infection and to describe their signs, symptoms, and laboratory findings. The surveillance definition of AIDS has proven to be extremely valuable and quite reliable for some epidemiologic studies and clinical assessment of patients with the more severe manifestations of disease. However, more inclusive definitions and classifications of HTLV- III/LAV infection are needed for optimum patient care, health planning, and public health control strategies, as well as for epidemiologic studies and special surveys. A broadly applicable, easily understood classification system should also facilitate and clarify communication about this disease.
In an attempt to formulate the most appropriate classification system, CDC has sought the advice of a panel of expert consultants ** to assist in defining the manifestations of HTLV-III/LAV infection.
GOALS AND OBJECTIVES OF THE CLASSIFICATION SYSTEM
The classification system presented in this report is primarily applicable to public health purposes, including disease reporting and surveillance, epidemiologic studies, prevention and control activities, and public health policy and planning.
Immediate applications of such a system include the classification of infected persons for reporting of cases to state and local public health agencies, and use in various disease coding and recording systems, such as the forthcoming 10th revision of the International Classification of Diseases.
DEFINITION OF HTLV-III/LAV INFECTION
The most specific diagnosis of HTLV-III/LAV infection is by direct identification of the virus in host tissues by virus isolation; however, the techniques for isolating HTLV-III/LAV currently lack sensitivity for detecting infection and are not readily available. For public health purposes, patients with repeatedly reactive screening tests for HTLV-III/LAV antibody (e.g., enzyme-linked immunosorbent assay) in whom antibody is also identified by the use of supplemental tests (e.g., Western blot, immunoflu- orescence assay) should be considered both infected and infective (8-10). Although HTLV-III/LAV infection is identified by isolation of the virus or, indirectly, by the presence of antibody to the virus, a presumptive clinical diagnosis of HTLV-III/LAV infection has been made in some situations in the absence of positive virologic or serologic test results. There is a very strong correlation between the clinical manifestations of AIDS as defined by CDC and the presence of HTLV-III/LAV antibody (11-14). Most persons whose clinical illness fulfills the CDC surveillance definition for AIDS will have been infected with the virus (12-14).
This system classifies the manifestations of HTLV-III/LAV infection into four mutually exclusive groups, designated by Roman numerals I through IV (Table 5). The classification system applies only to patients diagnosed as having HTLV-III/LAV infection (see previous section, DEFINITION OF HTLV- III/LAV INFECTION). Classification in a particular group is not explicitly intended to have prognostic significance, nor to designate severity of illness. However, classification in the four principal groups, I-IV, is hierarchical in that persons classified in a particular group should not be reclassified in a preceding group if clinical findings resolve, since clinical improvement may not accurately reflect changes in the severity of the underlying disease.
Group I includes patients with transient signs and symptoms that appear at the time of, or shortly after, initial infection with HTLV-III/LAV as identified by laboratory studies. All patients in Group I will be reclassified in another group following resolution of this acute syndrome.
Group II includes patients who have no signs or symptoms of HTLV-III/LAV infection. Patients in this category may be subclassified based on whether hematologic and/or immunologic laboratory studies have been done and whether results are abnormal in a manner consistent with the effects of HTLV-III/LAV infection.
Group III includes patients with persistent generalized lymphadenopathy, but without findings that would lead to classification in Group IV. Patients in this category may be subclassified based on the results of laboratory studies in the same manner as patients in Group II.
Group IV includes patients with clinical symptoms and signs of HTLV- III/LAV infection other than or in addition to lymphadenopathy. Patients in this group are assigned to one or more subgroups based on clinical findings. These subgroups are: A. constitutional disease; B. neurologic disease; C. secondary infectious diseases; D. secondary cancers; and E. other conditions resulting from HTLV-III/LAV infection. There is no a priori hierarchy of severity among subgroups A through E, and these subgroups are not mutually exclusive.
Definitions of the groups and subgroups are as follows:
Group I. Acute HTLV-III/LAV Infection. Defined as a mononucleosis-like syndrome, with or without aseptic meningitis, associated with seroconversion for HTLV-III/LAV antibody (15-16). Antibody seroconversion is required as evidence of initial infection; current viral isolation procedures are not adequately sensitive to be relied on for demonstrating the onset of infection.
Group II. Asymptomatic HTLV-III/LAV Infection. Defined as the absence of signs or symptoms of HTLV-III/LAV infection. To be classified in Group II, patients must have had no previous signs or symptoms that would have led to classification in Groups III or IV. Patients whose clinical findings caused them to be classified in Groups III or IV should not be reclassified in Group II if those clinical findings resolve.
Patients in this group may be subclassified on the basis of a laboratory evaluation. Laboratory studies commonly indicated for patients with HTLV- III/LAV infection include, but are not limited to, a complete blood count (including differential white blood cell count) and a platelet count. Immuno- logic tests, especially T-lymphocyte helper and suppressor cell counts, are also an important part of the overall evaluation. Patients whose test results are within normal limits, as well as those for whom a laboratory evaluation has not yet been completed, should be differentiated from patients whose test results are consistent with defects associated with HTLV-III/LAV infection (e.g., lymphopenia, thrombocytopenia, decreased number of helper (T((4))) T- lymphocytes).
Group III. Persistent Generalized Lymphadenopathy (PGL). Defined as palpable lymphadenopathy (lymph node enlargement of 1 cm or greater) at two or more extra-inguinal sites persisting for more than 3 months in the absence of a concurrent illness or condition other than HTLV-III/LAV infection to explain the findings. Patients in this group may also be subclassified on the basis of a laboratory evaluation, as is done for asymptomatic patients in Group II (see above). Patients with PGL whose clinical findings caused them to be classified in Group IV should not be reclassified in Group III if those other clinical findings resolve.
Group IV. Other HTLV-III/LAV Disease. The clinical manifestations of patients in this group may be designated by assignment to one or more subgroups (A-E) listed below. Within Group IV, subgroup classification is independent of the presence or absence of lymphadenopathy. Each subgroup may include patients who are minimally symptomatic, as well as patients who are severely ill. Increased specificity for manifestations of HTLV-III/LAV infection, if needed for clinical purposes or research purposes or for disability determinations, may be achieved by creating additional divisions within each subgroup.
Subgroup A. Constitutional disease. Defined as one or more of the following: fever persisting more than 1 month, involuntary weight loss of greater than 10% of baseline, or diarrhea persisting more than 1 month; and the absence of a concurrent illness or condition other than HTLV- III/LAV infection to explain the findings.
Subgroup B. Neurologic disease. Defined as one or more of the following: dementia, myelopathy, or peripheral neuropathy; and the absence of a concurrent illness or condition other than HTLV-III/LAV infection to explain the findings.
Subgroup C. Secondary infectious diseases. Defined as the diagnosis of an infectious disease associated with HTLV-III/LAV infection and/or at least moderately indicative of a defect in cell-mediated immunity. Patients in this subgroup are divided further into two categories:
Category C-1. Includes patients with symptomatic or invasive disease due to one of 12 specified secondary infectious diseases listed in the surveillance definition of AIDS ***: Pneumocystis carinii pneumonia, chronic cryptosporidiosis, toxoplasmosis, extra- intestinal strongyloidiasis, isosporiasis, candidiasis (esophageal, bronchial, or pulmonary), cryptococcosis, histoplasmosis, mycobacterial infection with Mycobacterium avium complex or M. kansasii, cytomegalovirus infection, chronic mucocutaneous or disseminated herpes simplex virus infection, and progressive multifocal leukoencephalopathy.
Category C-2. Includes patients with symptomatic or invasive disease due to one of six other specified secondary infectious diseases: oral hairy leukoplakia, multidermatomal herpes zoster, recurrent Salmonella bacteremia, nocardiosis, tuberculosis, or oral candidiasis (thrush).
Subgroup D. Secondary cancers. Defined as the diagnosis of one or more kinds of cancer known to be associated with HTLV-III/LAV infection as listed in the surveillance definition of AIDS and at least moderately indicative of a defect in cell-mediated immunity ****: Kaposi's sarcoma, non-Hodgkin's lymphoma (small, noncleaved lymphoma or immunoblastic sarcoma), or primary lymphoma of the brain.
Subgroup E. Other conditions in HTLV-III/LAV infection. Defined as the presence of other clinical findings or diseases, not classifiable above, that may be attributed to HTLV-III/LAV infection and/or may be indicative of a defect in cell-mediated immunity. Included are patients with chronic lymphoid interstitial pneumonitis. Also included are those patients whose signs or symptoms could be attributed either to HTLV-III/LAV infection or to another coexisting disease not classified elsewhere, and patients with other clinical illnesses, the course or management of which may be comp- licated or altered by HTLV-III/LAV infection. Examples include: patients with constitutional symptoms not meeting the criteria for sub-group IV-A; patients with infectious diseases not listed in subgroup IV-C; and patients with neoplasms not listed in subgroup IV-D.
Reported by Center for Infectious Diseases, CDC.
Editorial Note: The classification system is meant to provide a means of grouping patients infected with HTLV-III/LAV according to the clinical expression of disease. It will require periodic revision as warranted by new information about HTLV-III/LAV infection. The definition of particular syndromes will evolve with increasing knowledge of the significance of certain clinical findings and laboratory tests. New diagnostic techniques, such as the detection of specific HTLV-III/LAV antigens or antibodies, may add specificity to the assessment of patients infected with HTLV-III/LAV.
The classification system defines a limited number of specified clinical presentations. Patients whose signs and symptoms do not meet the criteria for other groups and subgroups, but whose findings are attributable to HTLV- III/LAV infection, should be classified in subgroup IV-E. As the classifi- cation system is revised and updated, certain subsets of patients in subgroup IV-E may be identified as having related groups of clinical findings that should be separately classified as distinct syndromes. This could be accom- plished either by creating additional subgroups within Group IV or by broadening the definitions of the existing subgroups.
Persons currently using other classification systems (6-7) or nomen- clatures (e.g., AIDS-related complex, lymphadenopathy syndrome) can find equivalences with those systems and terminologies and the classification presented in this report. Because this classification system has only four principal groups based on chronology, presence or absence of signs and symptoms, and the type of clinical findings present, comparisons with other classifications based either on clinical findings or on laboratory assessment are easily accomplished.
This classification system does not imply any change in the definition of AIDS used by CDC since 1981 for national reporting. Patients whose clinical presentations fulfill the surveillance definition of AIDS are classified in Group IV. However. not every case in Group IV will meet the surveillance definition.
Persons wishing to comment on this material are encouraged to send comments in writing to the AIDS Program, Center for Infectious Diseases, CDC.
The AIDS virus has been variously termed human T-lymphotropic virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV), or human immunodeficiency virus (HIV). The designation human immunodeficiency virus (HIV) has recently been proposed by a subcom- mittee of the International Committee for the Taxonomy of Viruses as the appropriate name for the retrovirus that has been implicated as the causative agent of AIDS (4).
** The following persons served on the review panel: DS Burke, MD, RR Redfield, MD, Walter Reed Army Institute of Research, Washington, DC; J Chin, MD, State Epidemiologist, California Department of Health Services; LZ Cooper, MD, St Luke's-Roosevelt Hospital Center, New York City; JP Davis, MD, State Epidemiologist, Wisconsin Division of Health; MA Fischl, MD, University of Miami School of Medicine, Miami, Florida; G Friedland, MD, Albert Einstein College of Medicine, New York City; MA Johnson, MD, DI Abrams, MD, San Francisco General Hospital; D Mildvan, MD, Beth Israel Medical Center, New York City; CU Tuazon, MD, George Washington University School of Medicine, Washington, DC; RW Price, MD, Memorial Sloan-Kettering Cancer Center, New York City; C Konigsberg, MD, Broward County Public Health Unit, Fort Lauderdale, Florida; MS Gottlieb, MD, University of California -- Los Angeles Medical Center; representatives of the National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health, Center for Infectious Diseases, CDC.
*** This subgroup includes patients with one of more of the specified infectious diseases listed whose clinical presentation fulfills the definition of AIDS as used by CDC for national reporting.
**** This subgroup includes those patients with one or more of the specified cancers listed whose clinical presentation fulfills the definition of AIDS as used by CDC for national reporting.
Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to email@example.com.
Page converted: 08/05/98
This page last reviewed 5/2/01